A better understanding of the oncogenic mechanisms of MyD88 mutations provides the reasoning for targeting TLR7 and TLR9 signaling for ABC-DLBCL therapy [105]. This evidence concerns the gene TLR9 and diffuse large B-cell lymphoma.